Skip to main content
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1992 May;35(3):193–198. doi: 10.1007/BF01756187

The polysaccharide K (PSK) potentiates in vitro activation of the cytotoxic function in human blood lymphocytes by autologous tumour cells

F Vánky 1,2,, P Wang 1,2, E Klein 1
PMCID: PMC11038900  PMID: 1638556

Abstract

We have studied the effect of polysaccharide K (PSK) in the in vitro recognition of ex vivo carcinoma, sarcoma and lymphoma cells by the autologous blood lymphocytes. In 4/25 experiments PSK treatment activated the lymphocytes for auto-tumour lysis. Tumour cells alone generated lytic activity both in short- (16 h) and in longterm (6 days) mixed lymphocyte/tumour cell cultures (MLTC), in 2/12 and 3/13 cases respectively. The tumours that activated the lymphocytes expressed high levels of major histocompatibility complex (MHC) class I molecules. In vitro cytokine (interferon γ and tumour necrosis factor α) treatment of the tumour cells elevated the amounts of class I antigens and the treated cells acquired stimulatory potential. When PSK was added to the MLTC, in which untreated tumour cells were used, lytic potential was induced in 9/13 short-term and in 11/12 long-term cultures. It is noteworthy that in the presence of PSK the untreated, negative or low-class-I-expressor tumours also activated the cytotoxic function of the lymphocytes in 4/5 long-term and in 6/7 short-term cultures. Even in the case of those lymphocytes that could be activated by PSK or tumour cells alone, the simultaneous exposure was more efficient. The effect of PSK was dose-dependent, being optimal at 1 µg/ml and 10 µg/ml. The presence of EDTA and/or cytochalasin B in the cytotoxic test performed with the activated effectors abrogated the lysis, indicating the requirement of contacts with the effector cells.

Key words: Polysaccharide K, Lymphocytes, Tumour cytotoxicity

References

  • 1.Böyum A. Separation of blood leukocytes, granulocytes and lymphocytes. Tissue Antigens. 1974;4:269–274. [PubMed] [Google Scholar]
  • 2.Ebina T, Koyiha H. Antitumor effector mechanism at a distant site in the double grafted tumor system of PSK, a protein bound Polysaccharide Preparation. Jpn J Cancer Res (Gann) 1988;79:957–964. doi: 10.1111/j.1349-7006.1988.tb00061.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Ebina T, Kohya H, Yamaguchi T, Ishida N. Anti-metastatic effect of biological respond modifiers in the “double grafed tumor system”. Jpn J Cancer Res (Gann) 1986;77:1034–1042. [PubMed] [Google Scholar]
  • 4.Greenberg PD. Adoptive T cell therapy of tumors. Mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol. 1991;49:281–355. doi: 10.1016/s0065-2776(08)60778-6. [DOI] [PubMed] [Google Scholar]
  • 5.Julius MH, Simpson E, Herzenberg LA. Rapid method for the isolation of functional thymus-derived murine lymphocytes. Eur J Immunol. 1974;3:645–649. doi: 10.1002/eji.1830031011. [DOI] [PubMed] [Google Scholar]
  • 6.Kano T, Kumashiro R, Tamada R, Kodama Y, Inokuchi K. Late results of postoperative long term cancer chemotherapy for advanced carcinoma of the stomach. Jpn J Surgery. 1981;11:291–296. doi: 10.1007/BF02468770. [DOI] [PubMed] [Google Scholar]
  • 7.Kondo M, Kato H, Yokoe N, Matsumura N, Hotta T, Masuda M. Activation of complement by immunostimulants, BCG, OK-432 (Picibanil) and PS.K (Krestin) in vitro. Gann. 1978;69:699–702. [PubMed] [Google Scholar]
  • 8.Tagushi T. Clinical study on PSK: combination of PSK with surgery and chemotherapy. Recent Results Cancer Res. 1979;68:236–240. doi: 10.1007/978-3-642-81332-0_36. [DOI] [PubMed] [Google Scholar]
  • 9.Timonen T, Saksela E, Ranki A, Häyry P. Fractionation, morphological and functional characterization of effector cells responsible for human natural killer activity against cell-line targets. Cell Immunol. 1979;48:133–148. doi: 10.1016/0008-8749(79)90106-0. [DOI] [PubMed] [Google Scholar]
  • 10.Tsukagoshi S, Ohashi F. Protein bound polysaccharide preparation, PS-K, effective against mouse sarcoma 180 and rat ascites hepatoma AH-13 by oral use. Gann. 1974;65:557–558. [PubMed] [Google Scholar]
  • 11.Tsukagoshi S, Hashimoto Y, Fujii G, Kobayashi H, Nomoto K, Orita K. Krestin (PSK) Cancer Treat Rev. 1984;11:131–155. doi: 10.1016/0305-7372(84)90005-7. [DOI] [PubMed] [Google Scholar]
  • 12.Vánky F, Stjernswärd J. Lymphocyte stimulation test for detection of tumor specific reactivity in humans. In: Wybran J, Staquet M, editors. Clinical tumor immunology. Oxford: Pergamon; 1976. pp. 55–58. [Google Scholar]
  • 13.Vánky F, Argov S, Klein E. Tumor biopsy cells participating in systems in which cytotoxicity of lymphocytes is generated. Autologous and allogeneic studies. Int J Cancer. 1981;27:273–280. doi: 10.1002/ijc.2910270304. [DOI] [PubMed] [Google Scholar]
  • 14.Vánky F, Péterffy A, Böök K, Willems J, Klein E, Klein G. Correlation between lymphocyte mediated auto-tumor reactivities and the clinical course: II. Evaluation of 69 patients with lung carcinoma. Cancer Immunol Immunother. 1983;16:17–22. doi: 10.1007/BF00199900. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Vánky F, Willems J, Kreicbergs A, Aparisi T, Andréen M, Bruström LÅ, Nilsonne U, Klein E, Klein G. Correlation between lymphocyte mediated auto-tumor reactivities and the clinical course: I. Evaluation of 46 patients with sarcoma. Cancer Immunol Immunother. 1983;16:11–16. doi: 10.1007/BF00199899. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Vánky F, Klein E, Willems J, Böök K, Ivert T, Péterffy A, Nilsonne U, Kreicbergs A, Aparisi T. Lysis of autologous tumor cells by blood lymphocytes tested at the time of surgery. Correlation with the postsurgical clinical course. Cancer Immunol Immunother. 1986;21:69–76. doi: 10.1007/BF00199380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Vánky F, Klein E, Willems J, Böök K, Ivert T, Péterffy A. Recognition of autologous tumor cells by blood lymphocytes in patients with lung cancer. In: Byers VE, Baldwin RW, editors. Immunology of malignant disease. London: MTP; 1987. pp. 105–127. [Google Scholar]
  • 18.Vánky F, Stuber G, Rotstein S, Klein E. Auto tumor recognition following in vitro induction of MHC antigen expression on solid human tumors: stimulation of lymphocytes and generation of cytotoxicity against the original MHC antigen negative tumor cells. Cancer Immunol Immunother. 1989;28:17–21. doi: 10.1007/BF00205795. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Vánky F, Wang P, Patarroyo M, Klein E. Expression of the adhesion molecule ICAM-1 and MHC class I antigens on human tumor cells are required for their interaction with autologous lymphocytes in vitro. Cancer Immunol Immunother. 1990;31:19–27. doi: 10.1007/BF01742491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Vose BM, Vánky F, Klein E. Lymphocyte cytotoxicity against autologous tumour biopsy cells in humans. Int J Cancer. 1977;20:512–519. doi: 10.1002/ijc.2910200407. [DOI] [PubMed] [Google Scholar]
  • 21.Yefenof E, Einat E, Klein E. Potentiation of T cell immunity against radiation-leukemia-virus-induced lymphoma by polysaccharide K. Cancer Immunol Immunother. 1991;34:133–137. doi: 10.1007/BF01741348. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES